መነሻ › ዲፊዩዝ ላርጅ ቢ-ሴል ሊምፎማ › ጆርጂያ
በጆርጂያ ለዲፊዩዝ ላርጅ ቢ-ሴል ሊምፎማ የሚደረጉ ክሊኒካዊ ጥናቶች
ለዲፊዩዝ ላርጅ ቢ-ሴል ሊምፎማ የሚደረጉ 15 ጥናቶች በጆርጂያ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በጆርጂያ ውስጥ ያሉ ከተሞች
Official study text (English)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Augusta University Georgia Cancer Center, Augusta
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06500273Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ ከ0 እስከ 38 · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06131801A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Augusta University, Augusta
- Southeastern Regional Medical Center, Newnan
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05006716A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- University Cancer & Blood Center, LLC ( Site 0141), Athens
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06717347A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Emory University Hospital, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07226843Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- City of Hope Atlanta Cancer Center, Newnan
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦገስ 2026 · NCT07365306Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Augusta University Medical Center, Augusta
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT05826535A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Winship Cancer Institute of Emory University, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ19 ኦገስ 2026 · NCT04104776A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Northside Hospital, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ኦገስ 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Winship Cancer Institute of Emory University, Atlanta
- Georgia Cancer Center at Augusta University, Augusta
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ጁላይ 2026 · NCT04792489Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT03501576A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Winship Cancer Institute of Emory University, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ጁላይ 2026 · NCT05131022SynKIR-310 for Relapsed/Refractory B-NHL
- Winship Cancer Institute of Emory University, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ኤፕሪ 2026 · NCT06544265Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ፌብሩ 2026 · NCT05633615DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Blood and Marrow Transplant Group of Georgia, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ7 ኤፕሪ 2023 · NCT04920617ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።